BACKGROUND: Intravascular hemolysis occurs after blood transfusion, in hemolytic anemias, and in other conditions, and is associated with hypercoagulable states. Hemolysis has been shown to potently activate platelets in vitro and in vivo, and several mechanisms have been suggested to account for this, including: (i) direct activation by hemoglobin (Hb); (ii) increase in reactive oxygen species (ROS); (iii) scavenging of nitric oxide (NO) by released Hb; and (iv) release of intraerythrocytic ADP. OBJECTIVE: To elucidate the mechanism of hemolysis-mediated platelet activation. METHODS: We used flow cytometry to detect PAC-1 binding to activated platelets for in vitro experiments, and a Siemens' Advia 120 hematology system to assess platelet aggregation by using platelet counts from in vivo experiments in a rodent model. RESULTS: We found that Hb did not directly activate platelets. However, ADP bound to Hb could cause platelet activation. Furthermore, platelet activation caused by shearing of red blood cells (RBCs) was reduced in the presence of apyrase, which metabolizes ADP to AMP. The use of ROS scavengers did not affect platelet activation. We also found that cell-free Hb enhanced platelet activation by abrogating the inhibitory effect of NO on platelet activation. In vivo infusions of ADP and purified (ADP-free) Hb, as well as hemolysate, resulted in platelet aggregation, as shown by decreased platelet counts. CONCLUSION: Two primary mechanisms account for RBC hemolysis-associated platelet activation: ADP release, which activates platelets; and cell-free Hb release, which enhances platelet activation by lowering NO bioavailability.
BACKGROUND:Intravascular hemolysis occurs after blood transfusion, in hemolytic anemias, and in other conditions, and is associated with hypercoagulable states. Hemolysis has been shown to potently activate platelets in vitro and in vivo, and several mechanisms have been suggested to account for this, including: (i) direct activation by hemoglobin (Hb); (ii) increase in reactive oxygen species (ROS); (iii) scavenging of nitric oxide (NO) by released Hb; and (iv) release of intraerythrocytic ADP. OBJECTIVE: To elucidate the mechanism of hemolysis-mediated platelet activation. METHODS: We used flow cytometry to detect PAC-1 binding to activated platelets for in vitro experiments, and a Siemens' Advia 120 hematology system to assess platelet aggregation by using platelet counts from in vivo experiments in a rodent model. RESULTS: We found that Hb did not directly activate platelets. However, ADP bound to Hb could cause platelet activation. Furthermore, platelet activation caused by shearing of red blood cells (RBCs) was reduced in the presence of apyrase, which metabolizes ADP to AMP. The use of ROS scavengers did not affect platelet activation. We also found that cell-free Hb enhanced platelet activation by abrogating the inhibitory effect of NO on platelet activation. In vivo infusions of ADP and purified (ADP-free) Hb, as well as hemolysate, resulted in platelet aggregation, as shown by decreased platelet counts. CONCLUSION: Two primary mechanisms account for RBC hemolysis-associated platelet activation: ADP release, which activates platelets; and cell-free Hb release, which enhances platelet activation by lowering NO bioavailability.
Authors: Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin Journal: Blood Date: 2005-11-15 Impact factor: 22.113
Authors: C J Foster; D M Prosser; J M Agans; Y Zhai; M D Smith; J E Lachowicz; F L Zhang; E Gustafson; F J Monsma; M T Wiekowski; S J Abbondanzo; D N Cook; M L Bayne; S A Lira; M S Chintala Journal: J Clin Invest Date: 2001-06 Impact factor: 14.808
Authors: Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin Journal: Nat Med Date: 2002-11-11 Impact factor: 53.440
Authors: D Praticó; M Pasin; O P Barry; A Ghiselli; G Sabatino; L Iuliano; G A FitzGerald; F Violi Journal: Circulation Date: 1999-06-22 Impact factor: 29.690
Authors: Mark T Gladwin; Alan N Schechter; Frederick P Ognibene; Wynona A Coles; Christopher D Reiter; William H Schenke; Gyorgy Csako; Myron A Waclawiw; Julio A Panza; Richard O Cannon Journal: Circulation Date: 2003-01-21 Impact factor: 29.690
Authors: Jeffrey Wang; Willard N Applefeld; Junfeng Sun; Steve B Solomon; Jing Feng; Zoe G Couse; Thomas F Risoleo; Robert L Danner; Jesús Tejero; Juan Lertora; Elmira Alipour; Swati Basu; Vandana Sachdev; Daniel B Kim-Shapiro; Mark T Gladwin; Harvey G Klein; Charles Natanson Journal: Am J Physiol Heart Circ Physiol Date: 2021-05-14 Impact factor: 4.733
Authors: Lorenzo Valerio; Jawaad Sheriff; Phat L Tran; William Brengle; Alberto Redaelli; Gianfranco B Fiore; Federico Pappalardo; Danny Bluestein; Marvin J Slepian Journal: Thromb Res Date: 2017-12-05 Impact factor: 3.944
Authors: Annalisa Dimasi; Marco Rasponi; Filippo Consolo; Gianfranco B Fiore; Danny Bluestein; Marvin J Slepian; Alberto Redaelli Journal: Med Eng Phys Date: 2017-08-30 Impact factor: 2.242
Authors: Phat L Tran; Maria-Grazia Pietropaolo; Lorenzo Valerio; William Brengle; Raymond K Wong; Toshinobu Kazui; Zain I Khalpey; Alberto Redaelli; Jawaad Sheriff; Danny Bluestein; Marvin J Slepian Journal: Perfusion Date: 2015-11-20 Impact factor: 1.972